Pretax income is the income that a company earns before paying income taxes. Editas Medicine's pretax income for the
three
months ended in Mar. 2024 was $-61.95 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was $-166.13 Mil.
Editas Medicine's pretax margin was -5,458.15%.
During the past 11 years, Editas Medicine's highest Pretax Margin was -127.82%. The lowest was -4475.14%. And the median was -753.61%.
Editas Medicine Pre-Tax Income Historical Data
The historical data trend for Editas Medicine's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Editas Medicine's Pre-Tax Income
For the Biotechnology subindustry, Editas Medicine's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Editas Medicine's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Editas Medicine's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Editas Medicine's Pre-Tax Income falls into.
Editas Medicine Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Editas Medicine's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-166.13 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Editas Medicine (NAS:EDIT) Pre-Tax Income Explanation
Editas Medicine's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as
During the past 11 years, Editas Medicine's highest Pretax Margin was -127.82%. The lowest was -4475.14%. And the median was -753.61%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Editas Medicine Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Editas Medicine's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Editas Medicine (Editas Medicine) Business Description
Editas Medicine Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EDIT has been successfully added to your 